Hudson Bay Capital Management
CLYM

Hudson Bay Capital Management’s Climb Bio CLYM Stock Holding History

Hudson Bay Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$373K Buy
54,460
+5,724
+12% +$33K ﹤0.01% 1010
2025
Q4 		$195K Buy
+48,736
New +$117K ﹤0.01% 975
2022
Q2 		– Sell
-100,000
Closed -$839K – 1432
2022
Q1 		$839K Hold
100,000
– – 0.01% 844
2021
Q4 		$1.05M Hold
100,000
– – 0.01% 786
2021
Q3 		$1.8M Buy
+100,000
New +$2.07M 0.02% 655

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Hudson Bay Capital Management's CLYM Position: Q1 2026 in Review

Hudson Bay Capital Management increased its Climb Bio (CLYM) stake by 12% in Q1 2026, buying an estimated $33K and bringing the position to 54,460 shares worth $373K. The position accounts for ﹤0.01% of the portfolio, ranked #1010.

Hudson Bay Capital Management first reported a position in CLYM in Q3 2021 and has held it in 5 quarters since. The position peaked at $1.8M in Q3 2021. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Hudson Bay Capital Management held 54,460 shares of Climb Bio worth $373K as of Q1 2026.
  • Hudson Bay Capital Management bought 5,724 Climb Bio shares in Q1 2026, an estimated $33K.
  • Climb Bio made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #1010 holding.
  • Hudson Bay Capital Management first reported a position in Climb Bio in Q3 2021 and has held it in 5 quarters since.
  • Hudson Bay Capital Management's Climb Bio position peaked at $1.8M in Q3 2021.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.